<DOC>
	<DOCNO>NCT01605019</DOCNO>
	<brief_summary>The purpose study evaluate use device call CoSeal™ . CoSeal™ FDA approve synthetic ( man-made ) surgical sealant currently use help stop leak blood vessel surgery . This study evaluate CoSeal™ apply various area heart surgery implant Left Ventricular Assist Device ( LVAD ) . investigator look evidence indicates CoSeal™ may useful reduce stop bleeding , occurrence micro embolus ( small particle air blood ) , formation cardiac adhesion ( scar tissue strand may form around heart area previous LVAD operation ) patient undergo LVAD implantation surgery .</brief_summary>
	<brief_title>The Use CoSeal ( Sealant Agent ) Patients During Left Ventricular Assist Device Surgery</brief_title>
	<detailed_description>This prospective , single-blind ( subject surgeon evaluator blind ) , randomize , multi-center , pilot study design evaluate effect CoSeal™ use surgical procedure implant LVAD . The study sample size 30 subject ; subject randomize 2:1 fashion , 20 subject randomize CoSeal™ Treatment Group 10 subject randomize sealant Control Group . Bioglue use control group , necessary . The Primary Objective prospective pilot study evaluate use CoSeal™ ability reduce bleed follow implantation LVAD . The secondary objective evaluate use CoSeal ability reduce micro embolus LVAD implant procedure prevent tissue adhesion follow implantation LVAD . CoSeal™ ( Baxter , Deerfield , Ill. , USA ) synthetic hydrogel consist two solution high molecular weight polyethylene glycol co-extruded liquid sodium phosphate buffer syringe housing unit . The device approve FDA use vascular reconstruction achieve adjunctive hemostasis mechanically seal area leakage show provide superior anastomatic suture line seal . In 2005 , CoSeal™ medical device also approve Europe Australia use patient undergoing cardiac surgery prevent reduce incidence , severity , extent post-surgical adhesion . Data study use support labeling change . This PI initiative study submit granted funding Baxter Healthcare data publishing study data .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<criteria>Subject subject 's legal representative sign IRB approve study inform consent . Subject great equal 18 year age . Subject know indication implantation LVAD meet requirement implantation . Subject , opinion investigator , require removal LVAD earlier 6 week implantation . Subject require concomitant use antiadhesion product LVAD implantation . Subject immune system disorder , immunodeficiency , immunosuppression . Subject know hypersensitivity study device , CoSeal™ , component study device . Subject currently participate another clinical trial adhesion prevention seal evaluation and/or receive investigational drug device within previous 30 day . Subject previously undergone LVAD implantation/explantation . Subject pregnant currently breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Ventricular Assist Devices</keyword>
	<keyword>Heart assist pump</keyword>
	<keyword>heart pump</keyword>
	<keyword>sealant agent</keyword>
</DOC>